Analysts Anticipate Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) Will Announce Earnings of -$1.13 Per Share

Wall Street brokerages expect Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) to report ($1.13) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Entasis Therapeutics’ earnings. The lowest EPS estimate is ($1.15) and the highest is ($1.10). Entasis Therapeutics posted earnings of ($20.33) per share in the same quarter last year, which would indicate a positive year over year growth rate of 94.4%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 13th.

According to Zacks, analysts expect that Entasis Therapeutics will report full-year earnings of ($4.03) per share for the current year, with EPS estimates ranging from ($4.21) to ($3.84). For the next year, analysts anticipate that the business will report earnings of ($3.36) per share, with EPS estimates ranging from ($3.76) to ($2.96). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Entasis Therapeutics.

Entasis Therapeutics (NASDAQ:ETTX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.44).

A number of analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Entasis Therapeutics in a research note on Monday, August 19th. They issued a “buy” rating and a $18.00 price objective for the company. Zacks Investment Research raised shares of Entasis Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Finally, ValuEngine raised shares of Entasis Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $16.75.

A hedge fund recently raised its stake in Entasis Therapeutics stock. Janney Montgomery Scott LLC grew its stake in shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 5.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,917 shares of the company’s stock after acquiring an additional 2,125 shares during the quarter. Janney Montgomery Scott LLC owned about 0.34% of Entasis Therapeutics worth $290,000 as of its most recent SEC filing. Institutional investors and hedge funds own 64.99% of the company’s stock.

Shares of ETTX traded down $0.12 during trading hours on Friday, reaching $5.68. 8,543 shares of the company traded hands, compared to its average volume of 28,841. The firm has a market cap of $73.68 million and a price-to-earnings ratio of -0.46. Entasis Therapeutics has a 12-month low of $3.97 and a 12-month high of $9.25. The company has a current ratio of 9.11, a quick ratio of 9.11 and a debt-to-equity ratio of 0.03. The stock’s fifty day moving average price is $6.66 and its 200 day moving average price is $6.53.

About Entasis Therapeutics

Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.

Further Reading: G-20

Get a free copy of the Zacks research report on Entasis Therapeutics (ETTX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Entasis Therapeutics (NASDAQ:ETTX)

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit